Signal Genetics is a commercial stage molecular genetic diagnostic company focused on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. Signal Genetics offers Myeloma Prognostic Risk Signature (MyPRS) test, a microarray-based gene expression profile assay to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma. For more information, visit the company’s website at www.signalgenetics.com